remifentanil + remimazolam (Yonsei University)

remifentanil + remimazolam is an investigational anesthesia combination regimen being evaluated by Yonsei University for total intravenous anesthesia (TIVA). This regimen combines remifentanil, an ultra-short-acting mu-opioid receptor agonist that provides potent analgesia, with remimazolam, a short-acting benzodiazepine that acts as a GABA-A receptor positive allosteric modulator to induce sedation. The combination is specifically being studied in the context of laparoscopic-assisted gastrectomy for patients with stomach neoplasms (gastric cancer) to assess its impact on postoperative pain and recovery compared to other opioid-sedative combinations like sufentanil-remimazolam.

Other names

remifentanil-remimazolamremifentanil-remimazolam TIVA